Skip to main content

Table 3 Time-to-onset analysis of bisphosphonates

From: Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events

Dosage form Drug name Case (number for analysis) Median of time-to-onset (day) Lower quartile of time-to-onset (day) Upper quartile of time-to-onset (day) Scale parameter: α Shape parameter: β
α (95 % CI) β (95 % CI)
Intravenous Alendronate (I.V.) 10 (6) 1,342 691 1,701 1267.6 (737.0 − 2125.0) 2.15 (0.96 − 3.83)
  Pamidronate 223 (118) 812 567 1,227 934.7 (816.9 − 1066.3) 1.45 (1.26 − 1.64)
  Zoledronate 809 (408) 486 274 821 631.5 (586.8 − 678.9) 1.41 (1.30 − 1.52)
Oral Alendronate (oral) 414 (196) 863 432 1,463 1095.4 (970.2 − 1233.8) 1.23 (1.09 − 1.37)
  Etidronate 16 (9) 1,461 389 2,068 1390.3 (766.8 − 2442.7) 1.49 (0.74 − 2.63)
  Minodronate 45 (32) 432 196 742 629.5 (408.3 − 954.8) 0.90 (0.69 − 1.13)
  Risedronate 152 (65) 730 215 1,494 951.7 (730.3 − 1228.7) 1.02 (0.82 − 1.24)